共 50 条
- [2] Pertuzumab in the Treatment of HER2+ Breast Cancer [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (04): : 591 - 598
- [3] The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data [J]. Health Economics Review, 11
- [7] COST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAINCO ST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAIN [J]. VALUE IN HEALTH, 2016, 19 (07) : A740 - A740
- [8] Pertuzumab in neoadjuvant treatment of HER2-positive early breast cancer [J]. JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2014, 12 (03): : 84 - 86
- [9] Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer [J]. Cancer Chemotherapy and Pharmacology, 2017, 79 : 353 - 361